MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$5,838,000
EPS
-$0.19
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenue
0 0 0 0
Research and development
3,073,000 2,002,000 1,681,000 4,292,000
General and administrative
2,157,000 1,957,000 3,811,000 2,579,000
Impairment loss on intangible assets
NaN 28,700,000 NaN NaN
Total operating expenses
5,230,000 32,659,000 5,492,000 6,871,000
Loss from operations
-5,230,000 -32,659,000 -5,492,000 -6,871,000
Other (expense) income, net
-608,000 -20,000 -89,000 49,000
Income tax benefit
NaN -712,000 NaN NaN
Net loss
-5,838,000 -31,967,000 -5,581,000 -6,822,000
Unrealized gain on investments, net of tax of 0
0 18,000 0 12,000
Foreign currency translation adjustments
0 -36,000 0 -24,000
Total other comprehensive loss
0 -18,000 0 -12,000
Total comprehensive loss
-5,838,000 -31,985,000 -5,581,000 -6,834,000
Basic EPS
-0.19 -1.091 -0.21 -0.28
Diluted EPS
-0.19 -1.091 -0.21 -0.28
Basic Average Shares
30,354,647 29,314,367 26,361,386 24,187,536
Diluted Average Shares
30,354,647 29,314,367 26,361,386 24,187,536
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Total comprehensiveloss-$5,838,000 (-5.86%↓ Y/Y)Net loss-$5,838,000 (-6.13%↓ Y/Y)Loss from operations-$5,230,000 (6.76%↑ Y/Y)Other (expense)income, net-$608,000 (-662.96%↓ Y/Y)Total operatingexpenses$5,230,000 (-6.76%↓ Y/Y)Research and development$3,073,000 (0.62%↑ Y/Y)General andadministrative$2,157,000 (-15.58%↓ Y/Y)

Rein Therapeutics, Inc. (RNTX)

Rein Therapeutics, Inc. (RNTX)